[go: up one dir, main page]

WO2008015383A8 - Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer - Google Patents

Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer Download PDF

Info

Publication number
WO2008015383A8
WO2008015383A8 PCT/GB2007/002755 GB2007002755W WO2008015383A8 WO 2008015383 A8 WO2008015383 A8 WO 2008015383A8 GB 2007002755 W GB2007002755 W GB 2007002755W WO 2008015383 A8 WO2008015383 A8 WO 2008015383A8
Authority
WO
WIPO (PCT)
Prior art keywords
bmp
breast
prostate cancer
cancer therapies
therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/002755
Other languages
English (en)
Other versions
WO2008015383A3 (fr
WO2008015383A2 (fr
Inventor
Wen Guo Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Cardiff University
Original Assignee
University College Cardiff Consultants Ltd
Cardiff University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd, Cardiff University filed Critical University College Cardiff Consultants Ltd
Publication of WO2008015383A2 publication Critical patent/WO2008015383A2/fr
Publication of WO2008015383A3 publication Critical patent/WO2008015383A3/fr
Anticipated expiration legal-status Critical
Publication of WO2008015383A8 publication Critical patent/WO2008015383A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne le rôle des protéines BMP-9 et/ou BMP-10 dans le traitement du cancer du sein ou de la prostate.
PCT/GB2007/002755 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer Ceased WO2008015383A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0615129.4A GB0615129D0 (en) 2006-07-29 2006-07-29 Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
GB0615129.4 2006-07-29

Publications (3)

Publication Number Publication Date
WO2008015383A2 WO2008015383A2 (fr) 2008-02-07
WO2008015383A3 WO2008015383A3 (fr) 2008-08-14
WO2008015383A8 true WO2008015383A8 (fr) 2009-07-16

Family

ID=37006438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/002755 Ceased WO2008015383A2 (fr) 2006-07-29 2007-07-20 Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer

Country Status (2)

Country Link
GB (1) GB0615129D0 (fr)
WO (1) WO2008015383A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891010C (fr) 2004-07-23 2022-09-20 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
EP1973559B1 (fr) 2005-11-23 2013-01-09 Acceleron Pharma Inc. Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (es) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
CN101687016B (zh) 2007-02-09 2014-12-31 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
US7960343B2 (en) 2007-09-18 2011-06-14 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for decreasing or inhibiting FSH secretion
WO2009084739A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp10
WO2009084738A1 (fr) * 2007-12-28 2009-07-09 Kyowa Hakko Kirin Co., Ltd. Procédé et composition pharmaceutique pour le traitement du cancer utilisant la protéine bmp9
ES2949049T3 (es) 2008-08-14 2023-09-25 Acceleron Pharma Inc Trampas de GDF
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
CN104840944A (zh) 2009-06-08 2015-08-19 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
EP3964224A1 (fr) 2012-11-02 2022-03-09 Celgene Corporation Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
JP7056932B2 (ja) 2015-08-25 2022-04-19 ヒスタイド アクツィエンゲゼルシャフト 組織形成誘導用化合物及びその使用
CA2998455A1 (fr) * 2015-09-17 2017-03-23 Histide Ag Association pharmaceutique pour convertir une cellule neoplasique en cellule non-neoplasique, et ses utilisations
EP3906932A3 (fr) * 2015-09-17 2021-12-01 Histide AG Association pharmaceutique pour la conversion d'une cellule neoplasique en cellule non-neoplasique et ses utilisations
US20240408175A1 (en) * 2021-10-18 2024-12-12 The Uab Research Foundation Bmp9 or an agonist thereof and its uses related to reducing metastasis of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226467T5 (es) * 1998-11-13 2009-08-27 Stryker Corporation Aliviamiento de los sintomas del cancer de prostata.
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006029406A2 (fr) * 2004-09-09 2006-03-16 Stryker Corporation Methodes de traitement de tumeurs osseuses

Also Published As

Publication number Publication date
WO2008015383A3 (fr) 2008-08-14
GB0615129D0 (en) 2006-09-06
WO2008015383A2 (fr) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2008015383A8 (fr) Activité anticancéreuse des protéines bmp-9 et bmp-10 et leur utilisation dans les traitements du cancer
WO2008076278A3 (fr) Procédés de traitements
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2007127010A3 (fr) Composés de diarylthiohydantoïne
EP1893196A4 (fr) Composes diarylhydantoines
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
IL199609A0 (en) Antifolate agent combinations in the treatment of cancer
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
WO2009053041A3 (fr) Identification de marqueurs associés aux tumeurs à des fins de diagnostic et de thérapie
WO2008089397A3 (fr) Marqueurs du cancer adrb2
WO2008150530A3 (fr) Molécules de liaison de cripto
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
IL185463A0 (en) Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
WO2008060945A3 (fr) Diagnostic et traitement du cancer du sein
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
MX2012001513A (es) Uso de melanocortinas para tratar la dislipidemia.
ZA200709542B (en) Combination therapy in the treatment of cancer
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
WO2009074253A3 (fr) Dérivés de phospholipide de clofarabine
WO2008009895A3 (fr) Matriptase-2
WO2008061048A3 (fr) Procédés et compositions permettant de diagnostiquer et de traiter le cancer de la prostate
WO2009046123A3 (fr) Antagonistes de nlrr-1 et leurs utilisations
AU2005339587A8 (en) Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07766318

Country of ref document: EP

Kind code of ref document: A2